Rafael Pharmaceuticals Appoints Senior Vice President for Clinical Development and Operations
May 13 2019 - 8:00AM
Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader
in the growing field of cancer metabolism-based therapeutics, today
announced the appointment of Mona M. Wahba, MD, MSM, as Senior Vice
President for Clinical Development and Clinical Operations.
Dr. Wahba’s impressive background includes her
success in creating and implementing high-value strategic vision
and clinical development (Phase I-IV), immunology, and nuclear
medicine, resulting in global submissions, approvals, launch and
growth of ten new products worldwide. She has developed a
successful working relationship with health authorities, including
the Food and Drug Administration (FDA), which resulted in smooth
label negotiations, approvals, and effective promotional
materials.
Sanjeev Luther, President and Chief Executive
Officer of Rafael Pharmaceuticals, commented, “We are thrilled to
welcome Dr. Wahba to our senior team at Rafael Pharmaceuticals. Her
successful and rich career has been guided by her deep passion
for patients, a quality aligning with our motto, ‘To Save A Life Is
To Save A Universe.’ We are confident that Dr. Wahba will provide
significant aid in our mission to develop
potential treatments for patients with pancreatic cancer, acute
myeloid leukemia and other difficult-to-treat cancers.”
Prior to joining Rafael Pharmaceuticals, Dr.
Wahba held executive positions in the pharmaceutical industry at
both large and small companies, including Pfizer, Bristol-Myers
Squibb, Novartis, Bayer, Taiho and Ipsen. She effectively created
and led large teams and franchises for maximum performance,
including joint ventures and alliances with different
organizations.
Dr. Wahba has a medical degree in addition
to a master’s degree in leadership and science management. Dr.
Wahba is a member of industry-respected organizations including
American Society of Clinical Oncology (ASCO), Society of Nuclear
Medicine and Molecular Imaging (SNMMI), European Society for
Medical Oncology (ESMO) and European Neuroendocrine Tumor Society
(ENETS).
About Rafael Pharmaceuticals,
Inc.Rafael Pharmaceuticals, Inc. is a clinical stage
company and a leader in the growing field of cancer
metabolism-based therapeutics. Rafael’s primary objective is to
develop and commercialize innovative, highly selective, well
tolerated and highly effective anti-cancer agents by selectively
targeting the altered metabolism in cancer cells. Rafael’s
first-in-class clinical lead compound, CPI-613®(devimistat), is
being evaluated in multiple ongoing/completed Phase I, II, and III
clinical studies. CPI-613®(devimistat) has been granted orphan drug
designation for the treatment of Pancreatic Cancer, Acute Myeloid
Leukemia (AML), Peripheral T-Cell Lymphoma (PTCL), Burkitt Lymphoma
and Myelodysplastic Syndromes (MDS). Rafael Pharmaceuticals is an
affiliate of Rafael Holdings, Inc. (NYSE AMERICAN: RFL). For more
information, visit http://www.rafaelpharma.com/.
Safe Harbor StatementThis press
release contains forward-looking statements. These statements
relate to future events or the company’s future financial
performance. In some cases, you can identify forward-looking
statements by terminology such as "may", "will", "should",
"expect", "plan", "anticipate", "believe", "estimate", "predict",
"potential" or "continue", the negative of such terms, or other
comparable terminology. These statements are only predictions.
Actual events or results may differ materially from those in the
forward-looking statements as a result of various important
factors. Although we believe that the expectations reflected in the
forward-looking statements are reasonable, such statements should
not be regarded as a representation by the company, or any other
person, that such forward-looking statements will be achieved. The
business and operations of the company are subject to substantial
risks which increase the uncertainty inherent in forward-looking
statements. We undertake no duty to update any of the
forward-looking statements, whether as a result of new information,
future events or otherwise.
In light of the foregoing, readers are cautioned
not to place undue reliance on such forward-looking statements.
###
Company Contact:Sanjeev
LutherPresident & CEO Rafael Pharmaceuticals, Inc.
sanjeev.luther@rafaelpharma.com
Media Contact:Vanessa
Donohuerafael@antennagroup.com 201-465-8036
Rafael (NYSE:RFL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rafael (NYSE:RFL)
Historical Stock Chart
From Sep 2023 to Sep 2024